Methylphenidate Effects on Symptoms of Attention Deficit Disorder in Adults

Mattes, Jeffrey A.; Boswell, Laine; Oliver, Herman

doi:10.1001/archpsyc.1983.01790220049008

Cited by 153 publications

(72 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…When mean dosage of methylphenidate increased at Weeks 8 to 10 (34.8 mg/day, 0.5 mg/kg/day), the superiority of atomoxetine disappeared. Although the dosage in our methylphenidate group is still lower than previous Western studies (0.6~1.1 mg/kg/day; Kessler et al, 2005;Mattes, Boswell, & Oliver, 1984;Wender, Reimherr, Wood, & Ward, 1985), most participants in our study were satisfied with the efficacy of 30 mg of IR-methylphenidate per day and decided to …”

Section: Core Symptoms and Severitymentioning

confidence: 62%

“…Fourth, the short study period limits our understanding of the long-term difference in treatment efficacy and adverse effects of IR-methylphenidate and atomoxetine. Finally, the relatively lower dosage than Western studies (Kessler et al, 2005;Mattes et al, 1984;Wender et al, 1985) but higher than Taiwan's clinical practice should be taken into account while interpreting our findings.…”

Section: Strengths and Limitationsmentioning

confidence: 90%

See 1 more Smart Citation

An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Adults With ADHD

Lin

Gau

et al. 2016

J Atten Disord

View full text Add to dashboard Cite

Objective: To directly compare the efficacy of methylphenidate and atomoxetine in improving symptoms, social functions, and quality of life among adults with ADHD. Method: This was an 8-to-10-week, open-label, head-to-head, randomized clinical trial with two treatment arms: immediate-release methylphenidate (IR-methylphenidate; n = 31) and atomoxetine once daily (n = 32). The outcome measures included ADHD symptom severity, quality of life, and functional impairments. Results: We found a significant reduction in overall ADHD symptoms and improvement in social functions and quality of life for both groups at Weeks 4 to 5 and Weeks 8 to 10. There was no significant difference in the slope of improvements over time except that atomoxetine was superior to IR-methylphenidate in reducing hyperactive/impulsive symptoms at Weeks 4 to 5. There was no significant group difference in the rates of adverse effects. Conclusion: Both IR-methylphenidate and atomoxetine are well tolerated and efficacious in ethnic Chinese adults with ADHD. (J. of Att.

show abstract

Section: Core Symptoms and Severitymentioning

confidence: 62%

Section: Strengths and Limitationsmentioning

confidence: 90%

An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Adults With ADHD

Lin

Gau

et al. 2016

J Atten Disord

View full text Add to dashboard Cite

show abstract

“…There are now several published RCTs which describe the efficacy of MPH in adult patients [95,[116][117][118][119][120][121][122]. Findings have revealed comparable effects of MPH in adults as those observed in children and adolescents [116, 120,123].…”

Section: Are Stimulants Efficacious and Well Tolerated By Both Sexes?mentioning

confidence: 99%

Stimulant Drug Effects on Attention Deficit/Hyperactivity Disorder: A Review of the Effects of Age and Sex of Patients

Cornforth¹,

Sonuga‐Barke²,

Coghill³

2010

CPD

View full text Add to dashboard Cite

Objective: Because dopamine functioning varies by sex and age it might be expected that the effects of methylphenidate or amfetamine, the psychostimulants used for the treatment of Attention Deficit /Hyperactivity Disorder (ADHD), will also be moderated by these factors.Here we review the published literature on whether stimulant effects in ADHD symptoms vary by age and sex. Results: Randomised controlled trials confirm that stimulant medication is efficacious for, and well tolerated by, males and females and patients across the age range; although preschoolers appear to have a less beneficial response and more side effects. Few studies that specifically examined the moderating effect of age and/or sex were identified. For sex, no effects on overall response were found, although one study reported that sex moderated methylphenidate pharmacodynamics. The few effects found for age were small and inconsistent. Conclusions:The available evidence suggests that stimulant medication, when appropriately administered, has efficacy as an ADHD treatment for both sexes and across all ages. There are currently too few published papers examining the effects of sex and age to draw strong conclusions about moderation. Further studies of the pharmacodynamics of stimulants on ADHD MEDICATION MODERATORS 3 symptoms measured using objective tests in the laboratory or classroom setting need to be undertaken.

show abstract

“…With methylphenidate the response rates ranged from 25% 45 to 78% 46 (compared with about 70% in children). The weakness of these studies lies in the absence of widely recognized diagnostic criteria, instruments to measure efficacy and 'therapeutic medication range'.…”

Section: Management Of Adult Adhdmentioning

confidence: 99%

What happens when children with attention deficit/hyperactivity disorder grow up?

Newton‐Howes

2004

JRSM

View full text Add to dashboard Cite

Attention deficit/hyperactivity disorder 1 and the associated hyperkinetic disorder, 2 hereafter both referred to as ADHD, are the most prevalent and best researched of all the childhood mental illnesses. Although not diagnostically identical, the combined type ADHD and ICD-10 hyperkinetic disorder have sufficient in common for research into the two to be considered in parallel. They are, as we shall see, common, disabling and probably neurobiologically based. The received wisdom over the years has been that ADHD is a disorder of childhood whose symptoms lessen over time; 3,4 consequently little attention was paid to the possibility that it might continue into adulthood. But is this old consensus correct? What does happen to the children who have ADHD?The diagnosis and treatment of ADHD is a perplexing area for the child and adolescent psychiatrist, and in the opinion of some clinicians and researchers the check-lists of the DSM-IV and ICD-10 do little justice to the psychosocial and behavioural aspects of hyperkinetic activities. 5 Moreover, review of the published work is hampered by the numerous changes in diagnostic criteria over the years. 6 The notion that ADHD phenomena reflect other disorders, rather than being core components of a nosologically separate identity, persisted (particularly in the UK) long after the discovery by Bradley in 1937 that stimulant medication has a calming effect on hyperactive children. 7 However, as the diagnostic tools have become more robust and the evidence to support pharmacological treatment has become stronger, the doubters are now in a minority. The attention dyscontrol-impulsivity-hyperactivity triad is widely accepted not only as a formal mental disorder but also as one whose diagnosis and management, both pharmacological and psychosocial, can offer profound benefit for the child and family.Because ADHD was diagnosed and managed principally by child and adolescent psychiatrists, the long-term fate of the patients suffered relative neglect. The likelihood of remission seemed to be supported by a steady reduction in symptoms over time. 8 However, the dearth of information has been substantially remedied over the past two decades and the possibility of ADHD as an adult diagnosis is gaining ground-opening treatment options for those affected. This paper explores existing knowledge and potential areas for further research. EPIDEMIOLOGY OF CHILD TO ADULT ADHDMost of the epidemiological studies into ADHD and its longitudinal trajectory have been conducted in the Americas and the UK. In children, ADHD is known to be a common condition: the prevalence of hyperkinetic disorder in 7-year-old boys in an inner-city British sample was 1.5%. 9 A community sample from Puerto Rico of children under 11 yielded a higher prevalence, 6.7%, 10 whilst that in an American paediatric population was 9.5%. 11 In a German survey of elementary school children, DSM-III criteria indicated a 9.6% prevalence of attention deficit disorders; however, use of DSM-IV raised this to 17.8%. 12 Clearly, some ...

show abstract

Methylphenidate Effects on Symptoms of Attention Deficit Disorder in Adults

Cited by 153 publications

References 22 publications

An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Adults With ADHD

An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Adults With ADHD

Stimulant Drug Effects on Attention Deficit/Hyperactivity Disorder: A Review of the Effects of Age and Sex of Patients

What happens when children with attention deficit/hyperactivity disorder grow up?

Contact Info

Product

Resources

About